文献速递认知障碍与痴呆

2015至2025年阿尔茨海默病临床试验疗效指标的系统综述

Efficacy Measures Used in Alzheimer Disease Clinical Trials Between 2015 and 2025: A Systematic Review.
PubMed 文献 · Neurology · 2026-07-23

结果显示95.4%的试验使用至少一个临床结局,73.5%使用至少一个生物标志物;认知、总体状态和功能能力是最常测量的临床域,但患者和照护者生活质量及疾病相关重大生活事件测量较少。仅21.8%的试验采用监管推荐的认知联合功能或总体状态的共同主要指标,8.4%仅以生物标志物作为主要疗效指标;共识别318种不同临床结局测量和219种不同生物标志物,使用高度异质。

要点

  • AD药物试验以认知、总体状态和功能能力为主要疗效域,生物标志物使用广泛。
  • 患者/照护者生活质量和疾病相关重大生活事件等患者有意义的结局测量频率低。
  • 疗效指标高度异质,仅少数试验采用监管推荐的共同主要指标,限制跨试验比较。

核心结论

  • AD药物试验疗效指标主要集中于认知、总体状态和功能结局,但患者和照护者其他有意义的临床域评估不足,生物标志物使用广泛。
  • 疗效指标使用存在显著异质性,限制跨试验比较,凸显建立标准化、共识性、临床有意义的核心测量集的必要性。

研究设计与样本

  • 系统综述,检索PubMed、Embase、Cochrane对照试验中心注册库和ClinicalTrials.gov。
  • 使用描述性统计总结以临床结局或生物标志物作为主要或次要疗效指标的比例、涉及的关键临床域及不同测量数量;研究注册于PROSPERO(CRD420251032087)。

主要发现

  • 95.4%(227/238)的试验使用至少一个临床结局,73.5%(175/238)使用至少一个生物标志物作为疗效指标。
  • 最常测量的临床域为认知能力(87.0%,207/238)、总体状态(76.9%,183/238)和功能能力(71.4%,170/238)。
  • 患者生活质量(16.0%,38/238)、照护者生活质量(8.8%,21/238)和显著疾病相关生活事件(2.5%,6/238)测量频率较低。
  • 仅21.8%(52/238)的试验采用监管推荐的认知联合功能或总体状态的共同主要指标,8.4%(20/238)仅以生物标志物作为主要疗效指标。
  • 共识别318种不同临床结局测量和219种不同生物标志物,分别仅6.9%(22/318)和6.8%(15/219)在超过5%的试验中使用。

关键数值与推荐

  • 监管推荐的共同主要指标为认知联合功能或总体状态,仅21.8%(52/238)的试验采用。
  • 8.4%(20/238)的试验以生物标志物作为唯一主要疗效指标。
  • 临床结局测量共318种,其中6.9%(22/318)在超过5%的试验中使用;生物标志物共219种,其中6.8%(15/219)在超过5%的试验中使用。

临床怎么用

  • 解读AD药物试验结果时需注意疗效指标的高度异质性,跨试验比较应谨慎。
  • 评估药物疗效时应关注认知、总体状态和功能能力等核心域,同时注意患者和照护者生活质量等患者有意义的结局可能未被充分测量。
  • 生物标志物广泛用作疗效指标,但仅少数试验以其作为唯一主要疗效指标,临床决策应结合临床结局综合判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Regulatory guidance has long emphasized clinically meaningful outcomes in Alzheimer disease (AD) drug trials. No contemporary review has examined the efficacy measures used for clinical trials of AD therapies. The objective of this study was to evaluate the clinical relevance and heterogeneity of efficacy measures used in phase II-IV AD drug trials over the past decade. METHODS: We systematically searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov. All phase II-IV clinical trials of pharmacologic therapies in individuals with mild cognitive impairment due to AD or mild-to-moderate AD that were published, completed, or terminated between January 1, 2015, and November 15, 2025, or still ongoing as of November 15, 2025, were eligible for inclusion. We summarized the proportion of trials using clinical outcomes or biomarkers as primary or secondary efficacy measures, key clinical domains addressed, and the number of distinct measures using descriptive statistics. This study is registered with PROSPERO (CRD420251032087). RESULTS: Among 238 included trials, 95.4% (227/238) used at least one clinical outcome and 73.5% (175/238) used at least one biomarker as efficacy measures. Cognitive abilities (87.0%, 207/238), global status (76.9%, 183/238), and functional ability (71.4%, 170/238) were the most frequently measured clinical domains, whereas patient (16.0%, 38/238) and caregiver (8.8%, 21/238) quality of life and significant disease-related life events (2.5%, 6/238) were less frequent. Only 21.8% (52/238) of trials adopted regulatory-recommended co-primary measures of cognition with either function or global status, whereas 8.4% (20/238) used biomarkers as the sole primary efficacy measure. We identified 318 distinct clinical outcome measures and 219 distinct biomarkers used across all trials, 6.9% (22/318) and 6.8% (15/219) of which were used in more than 5% of trials. DISCUSSION: Efficacy measures in AD drug trials primarily focused on cognition, global status, and functional outcomes, which are important indicators of AD progression. However, other clinical domains that may also be meaningful to patients and caregivers were far less frequently assessed, while biomarker use is widespread. Substantial heterogeneity in efficacy measure use limits comparability across trials and highlights the need for standardized, consensus-based, clinically meaningful core measure sets for AD drug trials.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Li C, Fu M, Berg K, et al. Efficacy Measures Used in Alzheimer Disease Clinical Trials Between 2015 and 2025: A Systematic Review. Neurology. 2026. PMID: 42492033. doi:10.1212/WNL.0000000000218373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。